Transcriptional profiling identifies altered intracellular labile iron homeostasis as a contributing factor to the toxicity of adaphostin: Decreased vascular endothelial growth factor secretion is independent of hypoxia-inducible factor-1 regulation

Clinical Cancer Research

Volumn 11, Issue 17, 2005, Pages 6370-6381

  Hose, Curtis ^a   Kaur, Gurmeet ^b   Sausville, Edward A ^b   Monks, Anne ^a  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADAPHOSTIN; DEFEROXAMINE; FERRITIN; HEAT SHOCK PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; IRON; IRON CHELATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFERRIN RECEPTOR; UBIQUITIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL DEATH; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IRON BALANCE; IRON CHELATION; IRON KINETICS; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTIONAL PROFILING; TUMOR CELL DESTRUCTION;

ADAMANTANE; ANTIOXIDANTS; CELL HYPOXIA; CULTURE MEDIA, CONDITIONED; DRUG COMBINATIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; HYDROQUINONES; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON; IRON CHELATING AGENTS; JURKAT CELLS; K562 CELLS; MOLECULAR STRUCTURE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; RECEPTORS, TRANSFERRIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 24344445225     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0291     Document Type: Article

References (34)

1. Kaur G, Gazit A, Levitzki A, et al. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K-562 chronic myelogenous leukemia. Anticancer Drugs 1994;5: 213-22.
2. Kaur G, Sausville EA. Altered physical state of p210bcr-abl in tyrphostin AG957-treated K-562 cells. Anticancer Drugs 1996;7:815-24.
3. Bhatia R, Munthe HA, Verfaillie CM. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores β1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia 1998;12:1708-17.
4. Losiewicz MD, Kaur G, Sausville EA. Different early effets of tyrphostin AG957 and geldanamycins on mitogen-activated protein kinase and p120cbl phosphorylation in anti CD-3-stimulated T-lymphoblasts. Biochem Pharmacol 1999;57:281-9.
5. Urbano A, Gorgun G, Foss F. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. Biochem Pharmacol 2002;63:689-92.
6. Svingen PA, Tefferi A, Kottke TJ, et al. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res 2000;6:237-49.
7. Mow BM, Chandra J, Svingen PA, et al. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 2002;99:664-71.
8. Avramis IA, Christodoulopoulos G, Suzuki A, et al. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother Pharmacol 2002;50:479-89.
9. Chandra J, Hackbarth J, Le S, et al. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 2003;102: 4512-9.
10. Yu C, Rahmani M, Almenara J, Sausville EA, Dent P, Grant S. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. Oncogene 2004;23: 1364-76.
11. Petrat F, de Groot H, Rauen U. Determination of the chelatable iron pool of single intact cells by laser scanning microscopy. Arch Biochem Biophys 2000;376: 74-81.
12. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.
13. Hentze MW, LC Kühn. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide and oxidative stress. Proc Natl Acad Sci U S A 1996;93: 8175-82.
14. Eisenstein RS. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 2000;20:627-62.
15. Theil EC. Regulation of ferritin and transferrin receptor mRNAs. J Biol Chem 1990;265:4771-4.
16. Theil EC, Eisenstein RS. Combinatorial mRNA regulation: iron regulatory proteins and iso-iron-responsive elements (Iso-IREs). J Biol Chem 2000; 275:40659-62.
17. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci 2004;1012:1-13.
18. Picard V, Epsztejn S, Santambrogio P, Cabantchik ZI, Beaumont CJ. Role of ferritin in the control of the labile iron pool in murine erythroleukemia cells. J Biol Chem 1998;273:15382-6.
19. Blancher C, Moore JW, Talks KL, Houlbrook S, Harris AL. Relationship of hypoxia-inducible factor (HIF)-1α and HIF-2α expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 2000; 60:7106-13.
20. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002;62:4316-24.
21. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64: 1475-82.
22. Epsztejn S, Glickstein H, Picard V, et al. H-ferritin subunit overexpression in erythroid cells reduces the oxidative stress responses and induces multidrug resistance properties. Blood 1999; 94:1-12.
23. Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem 2002;277: 17179-87.
24. Corna G, Santambrogio P, Minotti G, Cairo G. Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem 2004;279: 13738-45.
25. Agrawal R, Sharma PK, Rao GS. Release of iron from ferritin by metabolites of benzene and superoxide radical generating agents. Toxicology 2001;168: 223-30.
26. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
27. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001;13:167-71.
28. Liu Q, Berchner-Pfannschmidt U, Moller U, et al. A Fenton reaction at the endoplasmic reticulum is involved in the redox control of hypoxia-inducible gene expression. Proc Natl Acad Sci U S A 2004;101: 4302-7.
29. Jones A, Fujiyama C, Blanche C, et al. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 α and hypoxia-inducible factor-2 α in human bladder tumors and cell lines. Clin Cancer Res 2001; 7:1263-72.
30. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
31. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci 2004; 1012:1-13.
32. Folkman J, Hanahan D. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
33. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth is a potential tumour angiogenesis factor in vivo. Nature 1992;359:845-7.
34. Folkman J. Fighting cancer by attacking its blood supply. Sci Am 1996;275:150-4.